Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-Terminus with indium-111 or technetium-99m

Javad Garousi, Sarah Lindbo, Bogdan Mitran, Jos Buijs, Anzhelika Vorobyeva, Anna Orlova, Vladimir Tolmachev, Sophia Hober

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

ABD-Derived Affinity Proteins (ADAPTs) is a novel class of engineered scaffold proteins derived from an albumin-binding domain of protein G. The use of ADAPT6 derivatives as targeting moiety have provided excellent preclinical radionuclide imaging of human epidermal growth factor 2 (HER2) tumor xenografts. Previous studies have demonstrated that selection of nuclide and chelator for its conjugation has an appreciable effect on imaging properties of scaffold proteins. In this study we performed a comparative evaluation of the anti-HER2 ADAPT having an aspartate-glutamate-Alanine-valine-Aspartate-Alanine-Asparagine-serine (DEAVDANS) N-Terminal sequence and labeled at C-Terminus with 99mTc using a cysteine-containing peptide based chelator, glycine-serine-serine-cysteine (GSSC), and a similar variant labeled with 111In using a maleimido derivative of 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic acid (DOTA) chelator. Both 99mTc-DEAVDANS-ADAPT6-GSSC and 111In-DEAVDANS-ADAPT6-GSSC-DOTA accumulated specifically in HER2-expressing SKOV3 xenografts. The tumor uptake of both variants did not differ significantly and average values were in the range of 19-21%ID/g. However, there was an appreciable variation in uptake of conjugates in normal tissues that resulted in a notable difference in the tumor-To-organ ratios. The 111In-DOTA label provided 2-6 fold higher tumor-To-organ ratios than 99mTc-GSSC and is therefore the preferable label for ADAPTs.

Original languageEnglish
Article number14780
JournalScientific Reports
Volume7
Issue number1
DOIs
Publication statusPublished - 1 Dec 2017
Externally publishedYes

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-Terminus with indium-111 or technetium-99m'. Together they form a unique fingerprint.

Cite this